Getein Biotech, Inc Stock price

Equities

603387

CNE100002RR9

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
9.1 CNY -2.05% Intraday chart for Getein Biotech, Inc -3.29% -17.27%
Sales 2021 1.4B 194M Sales 2022 1.82B 252M Capitalization 6.34B 877M
Net income 2021 399M 55.22M Net income 2022 499M 69.06M EV / Sales 2021 4.4 x
Net cash position 2021 1.09B 150M Net cash position 2022 566M 78.39M EV / Sales 2022 3.17 x
P/E ratio 2021
18.2 x
P/E ratio 2022
12.8 x
Employees 2,508
Yield 2021
1.7%
Yield 2022
2.72%
Free-Float 52.62%
More Fundamentals * Assessed data
Dynamic Chart
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Meihua International Unit, Getein Biotech to Develop COVID-19 Antigen Test Kits, Other In Vitro Diagnostic Products MT
Meihua International Medical Technologies Co., Ltd. Enters into Strategic Partnership with Getein Biotech Inc. to Jointly Produce and Sell Covid-19 Antigen Test Kits and IVDs CI
Getein Biotech Gets Regulatory Approval for COVID-19 Kit; Shares Up 9% MT
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Yestar Healthcare, Getein Biotech End Investment Talks MT
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Yestar Healthcare Holdings Company Limited cancelled the transaction announced on April 8, 2022 CI
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Yestar Healthcare Holdings Company Limited announced that it expects to receive funding from Getein Biotech, Inc CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Sichuan Getein Biotechnology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Getein Biotech, Inc CI
More news
1 day-2.05%
1 week-3.29%
Current month+0.78%
1 month-2.99%
3 months-15.66%
6 months-19.68%
Current year-17.27%
More quotes
1 week
8.79
Extreme 8.79
9.94
1 month
8.54
Extreme 8.54
9.94
Current year
7.44
Extreme 7.44
11.17
1 year
7.44
Extreme 7.44
14.66
3 years
7.44
Extreme 7.44
20.87
5 years
7.44
Extreme 7.44
23.69
10 years
7.44
Extreme 7.44
23.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 02-03-07
Director of Finance/CFO 41 12-12-31
Director/Board Member 38 11-12-31
Members of the board TitleAgeSince
Director/Board Member 62 22-09-15
Chief Executive Officer 58 02-03-07
Director/Board Member 42 09-12-31
More insiders
Date Price Change Volume
24-03-27 9.1 -2.05% 14 522 020
24-03-27 9.29 +2.77% 17,140,880
24-03-26 9.04 +1.35% 3,666,100
24-03-25 8.92 -3.04% 3,245,723
24-03-22 9.2 -1.81% 3,496,434

End-of-day quote Shanghai S.E., March 27, 2024

More quotes
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
More about the company
  1. Stock
  2. Equities
  3. Stock Getein Biotech, Inc - Shanghai S.E.